Associated Papers
A rare large cell variant of small-cell carcinoma of the ovary, hypercalcemic type in a postmenopausal woman: Case report.
Liu S et al.
Medicine, 2025
Brief Report: The Effectiveness of Osimertinib in Advanced Nonsmall Cell Lung Cancer Harboring Various EGFR Exon 19 Mutation Variants.
Chang LC et al.
Clinical Lung Cancer, 2025
The evolutionary impact of childhood cancer on the human gene pool.
Stoltze UK et al.
Nature Communications, 2024
ERBB family fusions are recurrent and actionable oncogenic targets across cancer types.
Schubert L et al.
Frontiers in Oncology, 2023
Mutational Analysis of EGFR Mutations in Non-Small Cell Lung Carcinoma-An Indian Perspective of 212 Patients.
Kaler AK et al.
International Journal of Environmental Research and Public Health, 2022
Somatic targeted mutation profiling of colorectal cancer precursor lesions.
Dos Santos W et al.
Bmc Medical Genomics, 2022
Preclinical assessment of combination therapy of EGFR tyrosine kinase inhibitors in a highly heterogeneous tumor model.
Ikeuchi H et al.
Oncogene, 2022
A Nationwide Study on the Impact of Routine Testing for EGFR Mutations in Advanced NSCLC Reveals Distinct Survival Patterns Based on EGFR Mutation Subclasses.
Koopman B et al.
Cancers, 2021
Targeting rare and non-canonical driver variants in NSCLC - An uncharted clinical field.
Volckmar AL et al.
Lung Cancer (amsterdam, Netherlands), 2021
Nationwide germline whole genome sequencing of 198 consecutive pediatric cancer patients reveals a high incidence of cancer prone syndromes.
Byrjalsen A et al.
Plos Genetics, 2020
Circulating tumour DNA in metastatic breast cancer to guide clinical trial enrolment and precision oncology: A cohort study.
Zivanovic Bujak A et al.
Plos Medicine, 2020
Colorectal adenocarcinoma-derived EGFR mutants are oncogenic and sensitive to EGFR-targeted monoclonal antibodies, cetuximab and panitumumab.
Kim N et al.
International Journal of Cancer, 2020
Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer.
Wen S et al.
The Oncologist, 2019
Integrative omics analyses broaden treatment targets in human cancer.
Sengupta S et al.
Genome Medicine, 2018
Oncogenic driver mutations, treatment, and EGFR-TKI resistance in a Caucasian population with non-small cell lung cancer: survival in clinical practice.
Faehling M et al.
Oncotarget, 2017
Profiling of potential driver mutations in sarcomas by targeted next generation sequencing.
Andersson C et al.
Cancer Genetics, 2016
Mutational profiling of colorectal cancers with microsatellite instability.
Lin EI et al.
Oncotarget, 2015
Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma.
Siroy AE et al.
The Journal of Investigative Dermatology, 2015
Epidermal growth factor receptor (EGFR) mutations and expression in squamous cell carcinoma of the esophagus in central Asia.
Abedi-Ardekani B et al.
Bmc Cancer, 2012
[Clinical observation of EGFR-TKI as a first-line therapy on advanced non-small cell lung cancer].
Li J et al.
Zhongguo Fei Ai Za Zhi = Chinese Journal of Lung Cancer, 2012
Mutations in epidermal growth factor receptor gene in esophageal squamous cell carcinoma patients in kashmir- a high incidence area of India.
Mir MM et al.
International Journal of Health Sciences, 2008
Genome wide SNP comparative analysis between EGFR and KRAS mutated NSCLC and characterization of two models of oncogenic cooperation in non-small cell lung carcinoma.
Blons H et al.
Bmc Medical Genomics, 2008
Epidermal growth factor receptor mutation in lung cancer are linked to bronchioloalveolar differentiation.
Blons H et al.
The American Journal of Surgical Pathology, 2006